Anonymous ID: bbb9af Aug. 2, 2024, 2:27 a.m. No.21337900   🗄️.is 🔗kun   >>8154 >>8301 >>8338 >>8342

Resources

Failed Bank List

 

This list includes banks, which have failed since October 1, 2000.

 

https://www.fdic.gov/resources/resolutions/bank-failures/failed-bank-list/

 

Showing 1 to 12 of 569 entries

Anonymous ID: bbb9af Aug. 2, 2024, 3:12 a.m. No.21337991   🗄️.is 🔗kun

https://pubchem.ncbi.nlm.nih.gov/patent/US-10703789-B2

 

A pharmaceutical composition which has a plurality of lipid nanoparticles that has a mean particle size of between 80 nm and 160 nm and contains a modified mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5′-cap, 5′-UTR, N1-methyl-pseudouridine, a 3′-UTR, and a poly-A region with at least 100 nucleotides.

 

 

The polynucleotide, primary construct, and mmRNA of the invention can be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection; (3) permit the sustained or delayed release (e.g., from a depot formulation of the polynucleotide, primary construct, or mmRNA); (4) alter the biodistribution (e.g., target the polynucleotide, primary construct, or mmRNA to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; and/or (6) alter the release profile of encoded protein in vivo. In addition to traditional excipients such as any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, excipients of the present invention can include, without limitation, lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with polynucleotide, primary construct, or mmRNA (e.g., for transplantation into a subject), hyaluronidase, nanoparticle mimics and combinations thereof. Accordingly, the formulations of the invention can include one or more excipients, each in an amount that together increases the stability of the polynucleotide, primary construct, or mmRNA, increases cell transfection by the polynucleotide, primary construct, or mmRNA, increases the expression of polynucleotide, primary construct, or mmRNA encoded protein, and/or alters the release profile of polynucleotide, primary construct, or mmRNA encoded proteins. Further, the primary construct and mmRNA of the present invention may be formulated using self-assembled nucleic acid nanoparticles.

 

Further, the primary construct and mmRNA of the present invention may be formulated using self-assembled nucleic acid nanoparticles

 

https://patents.google.com/patent/US10703789B2